Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do…
31,010$
2,48%
Echtzeit-Aktienkurs Stoke Therapeutics
Bid:
Ask:
Nachrichten zur Stoke Therapeutics Aktie
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
…
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.…
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.…
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline
In recent days, Stoke Therapeutics and Biogen reported that data on the investigational Dravet syndrome medicine zorevunersen were published in…
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -20.37% and +69.03%, respectively, for the quarter ended September 2025. Do…
Stoke Therapeutics stock rises after appointing Ian Smith as CEO By Investing.com
Stoke Therapeutics stock rises after appointing Ian Smith as CEO…
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics (STOK) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this…
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 613.51% and 1,391.01%, respectively, for the quarter ended March 2025. Do…
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
…
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.…
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday - Altimmune (NASDAQ:ALT), Bitdeer Technologies (NASDAQ:BTDR)
…
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
…
Stoke Therapeutics STK-001: A Potential Game-Changer For Dravet Syndrome
…
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
…
Stoke Therapeutics prices upsized equity offering of $125M
…
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.…
Stoke Therapeutics Inc. surges following impressive study data By Investing.com
Stoke Therapeutics Inc. surges following impressive study data…
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 3.23% and 24.34%, respectively, for the quarter ended December 2023. Do…
Stoke therapeutics CFO sells over $25k in company stock By Investing.com
Stoke therapeutics CFO sells over $25k in company stock…
Stoke Therapeutics executive sells over $25k in company stock By Investing.com
Stoke Therapeutics executive sells over $25k in company stock…